1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Valiant Laboratories Limited

Valiant Laboratories Limited

VALIANTLAB.NS
Valiant Laboratories LimitedIN flagNational Stock Exchange of India
65.51
INR
+0.50
- -
3.56BMarket Cap

Total Valuation

Valiant Laboratories Limited carries a market capitalization of 3.56B, placing it among publicly traded companies globally. Its enterprise value stands at 2.78B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.56B
Enterprise Value2.78B

Share Statistics

Valiant Laboratories Limited currently has 54.31M shares outstanding.

Shares Outstanding54.31M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

Valiant Laboratories Limited trades at a trailing price-to-earnings ratio of 3,977.30. The price-to-sales ratio is 1.11, and the price-to-book ratio stands at 4.87.

PE Ratio3,977.30
PS Ratio1.11
PB Ratio4.87
P/TBV Ratio0.85
P/FCF RatioN/A
P/OCF RatioN/A

Enterprise Valuation

On an enterprise value basis, Valiant Laboratories Limited trades at an EV/EBITDA multiple of 762.95 and an EV/FCF ratio of 2,884.58. The EV/Sales ratio of 1.17 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 762.95 provides insight into valuation relative to core operating earnings.

EV / Sales1.17
EV / EBITDA762.95
EV / EBIT762.95
EV / FCF2,884.58

Financial Position

Valiant Laboratories Limited maintains a current ratio of 1.91, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 14.86, indicating elevated leverage, while an interest coverage ratio of 0.19 demonstrates limited ability to service its debt obligations.

Current Ratio1.91
Quick Ratio0.28
Debt / Equity14.86
Debt / EBITDA126.99
Interest Coverage0.19

Financial Efficiency

Valiant Laboratories Limited posts a return on equity of -4.44 and a return on invested capital of -0.43.

Return on Equity (ROE)-4.44
Return on Assets (ROA)-0.76
Return on Invested Capital (ROIC)-0.43
Return on Capital Employed (ROCE)-7.13
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover7.98

Taxes

Over the trailing twelve months, Valiant Laboratories Limited has paid 40.59M in income taxes, reflecting an effective tax rate of 519.06.

Income Tax40.59M
Effective Tax Rate519.06

Stock Price Statistics

Valiant Laboratories Limited's stock has declined approximately -43.2863% over the past 52 weeks. The 50-day moving average sits at 73.66, while the 200-day moving average is 69.57.

Beta (5Y)N/A
52-Week Price Change-43.2863%
50-Day Moving Average73.66
200-Day Moving Average69.57
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Valiant Laboratories Limited generated 2.37B in revenue and converted that into -32.76M in net income, yielding earnings per share of -0.64. EBITDA reached 3.64M, while operating income came in at 3.64M.

Revenue2.37B
Gross Profit403.18M
Operating Income3.64M
Pretax Income7.82M
Net Income-32.76M
EBITDA3.64M
EBIT3.64M
Earnings Per Share (EPS)-0.64

Balance Sheet

Valiant Laboratories Limited holds 331.50M in cash and equivalents against 462.12M in total debt, resulting in a net debt position of 414.21M. Total book value stands at 543.13M, with working capital of 1.09B providing operational flexibility.

Cash & Cash Equivalents331.50M
Total Debt462.12M
Net Debt414.21M
Equity (Book Value)543.13M
Book Value Per Share10.55
Working Capital1.09B

Margins

Valiant Laboratories Limited operates with a gross margin of 16.98, reflecting its pricing power and cost economics. The operating margin of 0.15 and net profit margin of -1.38 provide insight into operational efficiency.

Gross Margin16.98
Operating Margin0.15
Pretax Margin0.33
Profit Margin-1.38
EBITDA Margin0.15

Scores

Valiant Laboratories Limited posts an Altman Z-Score of 1.83, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.83